Eli Lilly reveals plans for new high-tech parenteral manufacturing site
Once operational in 2027, Eli Lilly’s new $2.5 billion German manufacturing site will play a vital role in supporting the company’s incretin supply.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
